The trajectory of companies tied to Sildenafil's past presents a intricate investment scenario . While the initial boom generated substantial profits , generic alternatives have significantly eroded revenue. Investing in related pharmaceutical businesses now requires a thorough assessment of patent safeguards, evolving medical shifts , and the poss